Clene Inc, formerly Chelsea Worldwide Inc., is a clinical-stage biopharmaceutical company. The Company through its subsidiary, Clene Nanomedicine, Inc., is focused on the development of therapeutics for neurodegenerative diseases. The Company has innovated a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. It has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The Company’s pipeline includes CNM-Au8, CNM-ZnAg, CNM-AgZn-17 and CNM-AuPt7. Its CNM-Au8 is a bioenergetic nanocatalyst, which enhances critical intracellular bioenergetic reactions necessary for repairing and reversing neuronal damage. CNM-AgZn17 is a topical gel polymer suspension of silver and zinc ions. Its CNM-PtAu7 is gold-platinum clean surfaced nanotechnology (CSN) therapeutic, which aims to address the unmet medical needs in several disease areas.